Agilent kicks off two partnerships with Australian universities

By Staff Writers
Wednesday, 20 October, 2010

Two Australian universities have received funding and technology from Agilent Technologies to help kick start new research initiatives.

The first is a glycoproteomics research project that will use liquid chromatography/mass sectrometry (LC/MS) to generate fragmentation data of glycoprotein glycans that will contribute to the publicly accessible GlycoSuite database.

This $100,000 project is funded by Macquarie University and Agilent in collaboration with the Australian Proteome Analysis Facility (APAF) and is headed by professor Nicolle Packer.

“The collaboration with Agilent will further enhance APAF’s capabilities to offer glycan analytical services to the biotech industry for the characterisation of recombinant glycoproteins which are emerging as important new drug therapies”, said Associate Professor Mark Molloy, APAF Director, in a statement.

The University of Sydney’s Bosch Institute also recently opened its new Oxidative Stress Bioanalytical Facility (OSBF), which the only dedicated lab worldwide for studying the impact of oxidative stress on tissue damage.

The OSBF is funded partially by an Australian Research Council Linkage Infrastructure, Equipment and Facilities (LIFE) grant in partnership with Agilent.

“The Bosch OSBF is unique in the world and it provides our researchers with a powerful platform to advance our understanding of the many diseases we study,” said Professor Jonathan Stone, the Executive Director of the Bosch Institute in a statement.

Related News

Vaccine for elephant herpesvirus found to be safe

The vaccine could prevent deadly elephant endotheliotropic herpesvirus in calves — the...

Pig-to-human liver xenotransplant conducted in a living recipient

The case involved a 71-year-old man with hepatitis B-related cirrhosis and hepatocellular...

Inhaled form of blood thinner treats serious COVID infections

Heparin has traditionally been injected and used to treat blood clots, but the new study tested...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd